PROCEPT BIOROBOTICS CORP (PRCT)
US74276L1052 - Common Stock
Taking everything into account, PRCT scores 4 out of 10 in our fundamental rating. PRCT was compared to 187 industry peers in the Health Care Equipment & Supplies industry. PRCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRCT shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year PRCT has reported negative net income.
In the past year PRCT has reported a negative cash flow from operations.
PRCT had negative earnings in each of the past 5 years.
PRCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PRCT has a Return On Assets (-27.70%) which is in line with its industry peers.
PRCT has a Return On Equity (-41.19%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.7% | ||
| ROE | -41.19% | ||
| ROIC | N/A |
ROA(3y)-24.03%
ROA(5y)-36.38%
ROE(3y)-34.78%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of PRCT (54.73%) is comparable to the rest of the industry.
PRCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRCT has more shares outstanding
PRCT has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 18.60 indicates that PRCT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 18.60, PRCT belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
A Debt/Equity ratio of 0.20 indicates that PRCT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, PRCT is in line with its industry, outperforming 52.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 18.6 |
ROIC/WACCN/A
WACC8.27%
2.3 Liquidity
A Current Ratio of 7.51 indicates that PRCT has no problem at all paying its short term obligations.
PRCT has a better Current ratio (7.51) than 84.49% of its industry peers.
A Quick Ratio of 6.49 indicates that PRCT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.49, PRCT belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.51 | ||
| Quick Ratio | 6.49 |
3. Growth
3.1 Past
PRCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.85%, which is quite good.
PRCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 73.74%.
The Revenue has been growing by 160.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)8.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
Revenue 1Y (TTM)73.74%
Revenue growth 3Y160.32%
Revenue growth 5YN/A
Sales Q2Q%61.17%
3.2 Future
Based on estimates for the next years, PRCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.27% on average per year.
The Revenue is expected to grow by 32.94% on average over the next years. This is a very strong growth
EPS Next Y14.09%
EPS Next 2Y15.29%
EPS Next 3Y17.31%
EPS Next 5Y16.27%
Revenue Next Year61.49%
Revenue Next 2Y50.53%
Revenue Next 3Y44.12%
Revenue Next 5Y32.94%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
PRCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PRCT's earnings are expected to grow with 17.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.29%
EPS Next 3Y17.31%
5. Dividend
5.1 Amount
PRCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROCEPT BIOROBOTICS CORP
NASDAQ:PRCT (9/18/2024, 8:23:12 PM)
After market: 83 +0.03 (+0.04%)82.97
+3.16 (+3.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.27B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.7% | ||
| ROE | -41.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.51 | ||
| Quick Ratio | 6.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)8.85%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y14.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)73.74%
Revenue growth 3Y160.32%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y